We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Zafgen announced Monday that the FDA has placed a hold on the first US clinical trial of ZGN-1061, the company's second-generation, investigational MetAP2 inhibitor under development for type 2 diabetes.